(Q36554410)

14 August 2017

1 reference

title

Case histories, magic bullets and the state of drug discovery (English)

1 reference

14 August 2017

1 reference

Jürgen Drews

1

1 reference

PubMed ID

16883301

14 August 2017

language of work or name

1 reference

13 April 2006

1 reference

Nature Reviews Drug Discovery

14 August 2017

1 reference

14 August 2017

5

1 reference

14 August 2017

635-640

1 reference

14 August 2017

8

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd2084

14 August 2017

0 references

cites work

The development of COX2 inhibitors

1 reference

Identification of a cyclooxygenase-related gene and its potential role in prostaglandin formation

31 March 2020

1 reference

Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase

31 March 2020

1 reference

Cyclooxygenases: structural, cellular, and molecular biology

31 March 2020

1 reference

The coxibs, selective inhibitors of cyclooxygenase-2.

31 March 2020

1 reference

Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic

31 March 2020

1 reference

31 March 2020

Cyclooxygenases 1 and 2

1 reference

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

31 March 2020

1 reference

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

31 March 2020

1 reference

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

31 March 2020

1 reference

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

31 March 2020

1 reference

Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery.

31 March 2020

1 reference

An audience with... Steven Nissen

31 March 2020

1 reference

COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs

31 March 2020

1 reference

Cyclooxygenase-2 as a therapeutic target

31 March 2020

1 reference

Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab

31 March 2020

1 reference

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

31 March 2020

1 reference

The development of experimental autoimmune encephalomyelitis in the mouse requires alpha4-integrin but not alpha4beta7-integrin

31 March 2020

1 reference

A controlled trial of natalizumab for relapsing multiple sclerosis.

31 March 2020

1 reference

Third Tysabri adverse case hits drug class

31 March 2020

1 reference

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

31 March 2020

1 reference

Activation of tyrosine kinases in cancer

31 March 2020

1 reference

Protein kinases--the major drug targets of the twenty-first century?

31 March 2020

1 reference

Targeting protein kinases

31 March 2020

1 reference

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

31 March 2020

1 reference

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

31 March 2020

1 reference

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

31 March 2020

1 reference

31 March 2020

1 reference

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

31 March 2020

1 reference

Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes

31 March 2020

1 reference

Structural rearrangements in the transmembrane glycoprotein after receptor binding

31 March 2020

1 reference

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

31 March 2020

1 reference

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

31 March 2020

1 reference

Modern biomedical research: an internally self-consistent universe with little contact with medical reality?

31 March 2020

1 reference

Can cell systems biology rescue drug discovery?

31 March 2020

1 reference

Innovation: Rescuing drug discovery: in vivo systems pathology and systems pharmacology

31 March 2020

1 reference

Drug research: myths, hype and reality

31 March 2020

1 reference

31 March 2020

1 reference

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD2084

1 reference

14 August 2017

1 reference

PubMed ID

16883301